From Lyophilization Process to Batch Consistency: A Discussion on Quality Control of Single-Tube Lyophilized Lymphocyte Subset Reagents

Effect of Lyophilization Process on Retention of Biological Activity

The quality foundation of a single-tube lyophilized reagent for lymphocyte subsets lies in the lyophilization process. During freeze-drying, antibodies may experience low temperature, hyperosmolarity, and interfacial stress. If the protectant formulation or drying curve is improperly set, fluorescence dye quenching or reduced antigen-binding capacity may occur. Manufacturers generally maintain antibody activity by optimizing the ratio of lyoprotectants (such as sugars, polyols, and protein stabilizers) and controlling the pre-freezing rate, primary drying temperature, and vacuum degree. If lyophilization curves differ between batches, drift in protein content or fluorescence intensity after reconstitution may occur; therefore, batch-to-batch consistency is a key focus of quality control.

Key Quality Indicators and Acceptance Points

When evaluating a single-tube lyophilized reagent for lymphocyte subsets, laboratories should not focus only on test results but should also examine several common indicators. For example, the appearance should be a uniform porous cake, and the reconstitution time for common specifications is usually required to be completed within a few minutes; after reconstitution, the liquid should be free of visible foreign matter, and the pH value should be within the range stated in the instructions; the positive rate and mean fluorescence intensity of the fluorescent antibodies should be close to those of the control reagent. In addition, the tolerance of the lyophilized reagent to temperature fluctuations during cold-chain transportation and storage also deserves attention. Laboratories are advised to check packaging integrity and temperature recorder data upon receipt.

Batch-to-Batch Consistency Verification Protocol in Flow Cytometry Testing

To reduce systematic error, laboratories may establish an internal verification protocol: after each new batch of single-tube lyophilized reagent for lymphocyte subsets arrives, use the same fresh whole blood sample to perform parallel testing with the existing batch and compare the deviations in the percentages and absolute counts of each subset. It is generally required that the results for key subsets fall within a preset allowable range; for example, the percentage deviation of common CD3+ T cells should not exceed a certain proportion (each laboratory may set this according to its precision objectives). At the same time, it is recommended to retain some batch samples as long-term quality control materials to observe stability changes of the lyophilized reagent within its shelf life.

Points of Attention at the Registration and Industry Regulation Level

As an in vitro diagnostic reagent, a single-tube lyophilized reagent for lymphocyte subsets must comply with the Regulations on the Supervision and Administration of Medical Devices and related classification provisions before being marketed in China. Usually, its management category may belong to Class II or Class III medical devices, and its safety and effectiveness should be verified through medical device registration testing and clinical trials (or exemption circumstances). Manufacturers need to establish a quality system compliant with the Good Manufacturing Practice for Medical Devices, validate lyophilization equipment, and audit raw material suppliers. When purchasing, users should verify the product's medical device registration certificate number, the scope of application in the instructions, and storage conditions, and avoid using unregistered products or products beyond their scope of application.

Routine Quality Control and Continuous Improvement

After introducing a single-tube lyophilized reagent for lymphocyte subsets, the clinical laboratory or flow cytometry laboratory should incorporate it into its routine quality control system. It is recommended to run quality control material at least once a week to monitor variation in the CD45/SSC gating region and the fluorescence intensity of each subset. If obvious batch-to-batch differences are found, factors such as reagent reconstitution procedures, sample collection time, and instrument optical path calibration should be investigated. Through record analysis and problem feedback, communicating improvement suggestions with the manufacturer helps drive the product's evolution from "easy to use" to "more stable." In summary, the technical advantages of lyophilized reagents ultimately need to be realized through strict quality management. Only when the process, acceptance, verification, and routine monitoring form a closed loop can reliable lymphocyte subset test results be provided for clinical use.